HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...

After nearly a decade of working as an advocate for HIV and AIDS treatment, Michael Chancley said he came to a sobering realization. “Seeing that people who look like me, who hang out at the same ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story 6-month HIV PrEP makes coverage gains ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Add Yahoo as a preferred source to see more of our stories on Google. Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or ...

Gilead's ad campaign aims to underscore that Yeztugo — its next-generation shot to stop HIV infection — is taken just twice a ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday ...

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) ...

A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them. And billing... Some patients face hurdles getting HIV prevention drugs.

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...